药学学报中英文刊、《CHM》、《JANPR》等杂志青年编委，中国分析测试协会医学质谱分会委员，四川省分析测试学会有机质谱专委会理事，中华中医药学会方药量效研究分会、中药基础理论分会委员等。

近五年主要承担课题：

1.国家自然科学基金-青年科学基金项目(B类)，临床价值导向的中药复方药效物质基础研究。

2.国家重点研发计划-“发育编程及其代谢调节”重点专项，免疫器官发育和稳态的代谢调控机制子课题。

3.国家自然科学基金-面上项目，基于解郁散热“把好气分关”探讨代谢-炎症“开关”A2BR在急性胰腺炎既病防变中的作用与机制。

4.国家自然科学基金-面上项目，丝氨酸代谢在急性胰腺炎发生发展中的作用及其调控氧化应激的分子机制。

5.四川省科技厅-国际科技创新合作项目，应用代谢组学研究柴芩承气汤治疗急性胰腺炎的作用机制。

 近五年以通讯/共同通讯发表主要文章：

1.Zhou JF, Zeng XX, Sun J, et al. Gut microbiota-derived indole-3-lactic acid suppresses anti-PD-1 efffcacy in esophageal squamous cell carcinoma. Cell Host Microb.2026, 34: 1-18.

2.Zhu C, Xu J, He S,et al. A Longitudinal Study Reveals Metabolomic Markers for Individuals at Risk, Disease Severity, and Treatment Response in Rheumatoid Arthritis. Adv Sci. 2025, 13: e04414.

3.Han C, Li L, Bai L,et al. Neurokinin 1 receptor inhibition alleviated mitochondrial dysfunction via restoring purine nucleotide cycle disorder driven by substance P in acute pancreatitis. Acta Pharm Sin B. 2025, 15(6): 3025-3040.

4.Gao J, Long YJ, Li J, et al. Geniposide, a potential therapeutical candidate for acute pancreaitis, inhibited trypsinogen-activated CBS degradation and remodeled transsulfuration metabolic flux. Redox Biol. 2025, 103900.

5.Shang C, Li W, Pu Q, et al. Targeting SCAMP2 by a Natural Product Auxarconjugatin B for Glioblastoma Therapy via Restoring Aspartate Metabolic Flux. Acta Pharm Sin B. 2025, 16(5): : 3090-3108.

6.Wu Y, Wang M, Wang R, et al. Novel Isotope-Coded Photochemical Derivatization Coupled with LC-MS and MS Imaging Platform Enables Sensitive Quantification and Accurate Localization of Amine Submetabolome in Pancreatic Disease. Anal Chem, 2025, 97(12): 6611–6619.

7.Zheng XY, Long YJ, Li L, et al. Chaihu shugan powder ameliorated chronic pancreatitis by reprogramming SMS2-mediated sphingolipid metabolism in M1 macrophages. Phytomedicine. 2025, 149: 157565.

8.Rong J, Han C, Huang Y, et a;. Inhibition of xanthine oxidase alleviated pancreatic necrosis via HIF-1α-regulated LDHA and NLRP3 signaling pathway in acute pancreatitis. Acta Pharm Sin B. 2024, 14(8): 3591-3604.